// App-Quantinova.ai

289 : Safety and tolerability of a subcutaneously administered tyrosine adsorbed modified mites allergen MIX + MPL

Researchers

Presenter

  • Roger A

Principal Investigators

  • Padr C

  • Hernndez D

  • Tabar A

  • Estany C

  • Justicia JL

  • De Kam PJ

Medical Centers

  • Hospital Germans Trias i Pujol, Barcelona, Spain

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • Complejo Hospitalario de Navarra, Pamplona, Spain

  • Allergy Therapeutics Ltd, Worthing, United Kingdom

Locations

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved